Answer
Yes, periodic skin examinations are recommended for all patients receiving upadacitinib hemihydrate, particularly those with risk factors for skin cancer.
Sources for this answer
- RINVOQ 15 mg prolonged-release tabletsAbbVie Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 28Document updated
Sources checked